Search | Clinical Trials Finder

Conditions: HIV Infections, Lipodystrophy
Interventions: Pravastatin sodium, Fenofibrate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 57
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more

Conditions: Hypercholesterolemia
Interventions: atorvastatin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Pravastatin; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Leukemia
Interventions: Bortezomib, Pravastatin; Drug
Lead sponsor: Reuven Schore; Other
Eligibility: 22 Months to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Pravastatin; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Systemic Lupus Erythematosus, Lupus
Interventions: pravastatin, aspirin, ramipril, Vitamins: B6, B12, and folate, heart health educational program; Drug · Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2002
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: Hypercholesterolaemia
Interventions: Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more

Conditions: Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80
Interventions: pravastatin and chenodeoxycholic acid, after metformin and placebo, valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Metabolic Disease
Interventions: Losartan, Zileuton, N-Acetylcysteine, Pravastatin, Erythromycin; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Combined Hyperlipidemia
Interventions: Pravafen, Pravastatin, Fenofibrate; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 57
States / cities: Phoenix, Arizona • Sierra Vista, Arizona • Long Beach, California + 46 more

Conditions: End-Stage Renal Disease, Chronic Allograft Nephropathy
Interventions: Irbesartan, Pravastatin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Cardiovascular Diseases
Interventions: AMR101, Placebo, Statin therapy; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 8,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 176
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more

Conditions: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Interventions: IDE196, Binimetinib, Crizotinib; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more

Conditions: Rheumatoid Arthritis
Interventions: BMS-986195, Methotrexate, Leucovorin, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions: cyclosporine, pravastatin sodium, mitoxantrone hydrochloride, etoposide, bone marrow aspiration; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Statin Adverse Reaction
Interventions: Statins, Placebo; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 40 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain
Interventions: Succinylcholine; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Sacramento, California • Golden, Colorado • Miami, Florida + 13 more

Conditions: HIV Infections, Hyperlipidemia
Interventions: Pravastatin, Darunavir, Ritonavir, Washout; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Fontan Circulation
Interventions: Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg), Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years); Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 8 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: HIV Infections, HIV Seronegativity, Lipodystrophy
Interventions: Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 10
States / cities: Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more

Conditions: Primary Dyslipidemia, Mixed Dyslipidemia
Interventions: pitavastatin, pravastatin; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 44
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 41 more

Search by objective public record fields.

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)

Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions

Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Prevention of Kidney Transplant Rejection

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Quality of Life in Patients With Statin-Associated Myopathy

Effect of Succinylcholine on Patients Using Statins

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia